UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 625

Sortiert nach

Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy

Clinical infectious diseases, 2001-01, Vol.32 (1), p.130-139

2001

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial of the safety and pharmacokinetics of cemiplimab, a human monoclonal antibody to programmed death-1, in Japanese patients with advanced malignancies, including expansion cohorts for patients with non-small-cell lung cancer

Annals of oncology, 2018-11, Vol.29, p.ix26-ix27

2018

Link zum Volltext

Verfügbarkeit prüfen

Health Care Utilization And Cost Associated With Radioiodine Refractory (Rai-R) Differentiated Thyroid Cancer (DTC)

Value in health, 2015-05, Vol.18 (3), p.A198-A198

2015

Link zum Volltext

Verfügbarkeit prüfen

Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)

Annals of oncology, 2018-10, Vol.29, p.viii414-viii414

2018

Link zum Volltext

Verfügbarkeit prüfen

Treatment Patterns and Persistence Among Patients Treated with Stivarga

Value in health, 2014-05, Vol.17 (3), p.A92-A92

2014

Link zum Volltext

Verfügbarkeit prüfen

Compare Demographic and Clinical Characteristics Among Colorectal Cancer Patients with a Different Number of Treatment Lines in the United States Veterans Health Administration

Value in health, 2014-05, Vol.17 (3), p.A91-A91

2014

Link zum Volltext

Verfügbarkeit prüfen

Health Care Cost and Utilization Among Patients Treated with Stivarga

Value in health, 2014-05, Vol.17 (3), p.A91-A92

2014

Link zum Volltext

Verfügbarkeit prüfen

Descriptive Analysis Of Treatment Patterns And Mortality Of United States Veteran Patients With Colorectal Cancer

Value in health, 2014-05, Vol.17 (3), p.A5-A5

2014

Link zum Volltext

Verfügbarkeit prüfen

2862 The influence of time to objective response on lenvatinib clinical outcomes in the phase 3 SELECT trial

European journal of cancer (1990), 2015-09, Vol.51, p.S577-S577

2015

Link zum Volltext

Verfügbarkeit prüfen

Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy

The journal of clinical endocrinology and metabolism, 2001-02, Vol.86 (2), p.504-510

2001

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of Hypogonadism among Men with Weight Loss Related to Human Immunodeficiency Virus Infection Who Were Receiving Highly Active Antiretroviral Therapy

Clinical infectious diseases, 2000-11, Vol.31 (5), p.1240-1244

2000

Link zum Volltext

Verfügbarkeit prüfen

Descriptive Analysis of Patients Initiating Regorafenib Therapy

Value in health, 2014-05, Vol.17 (3), p.A98-A99

2014

Link zum Volltext

Verfügbarkeit prüfen

1503TiP A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50

Annals of oncology, 2023-10, Vol.34, p.S846-S846

2023

Link zum Volltext

Verfügbarkeit prüfen

Evaluating Costs and Utilization of Prostate Cancer Patients with Bone Metastases in the Outpatient Hospital Setting

Value in health, 2014-05, Vol.17 (3), p.A76-A76

2014

Link zum Volltext

Verfügbarkeit prüfen

1443P Patient-reported outcomes (PROs) with cemiplimab plus chemotherapy (CEMI + CHEMO) for first-line treatment of advanced non-small cell lung cancer (aNSCLC): PD-L1 level subgroups in EMPOWER-Lung 3

Annals of oncology, 2023-10, Vol.34, p.S821-S821

2023

Link zum Volltext

Verfügbarkeit prüfen

P2.05-04 Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S308-S309

2023

Link zum Volltext

Verfügbarkeit prüfen

P2.06-10 Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S321

2023

Link zum Volltext

Verfügbarkeit prüfen

1105P Outcomes of real-world (RW) patients (pts) with advanced NSCLC (aNSCLC) and high programmed cell death-ligand 1 (PD-L1) expression receiving first line (1L) immune checkpoint inhibitor (ICI) therapy

Annals of oncology, 2022-09, Vol.33, p.S1056

2022

Link zum Volltext

Verfügbarkeit prüfen

1183P Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 1 histology subgroups

Annals of oncology, 2022-09, Vol.33, p.S1089

2022

Link zum Volltext

Verfügbarkeit prüfen

112P Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation

Annals of oncology, 2022-04, Vol.33, p.S84-S85

2022

Link zum Volltext

Verfügbarkeit prüfen

P1.15-12 Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S125-S126

2022

Link zum Volltext

Verfügbarkeit prüfen

334P Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Geographic region subgroups in EMPOWER-Lung 1

Annals of oncology, 2022-11, Vol.33, p.S1573

2022

Link zum Volltext

Verfügbarkeit prüfen

MA05.11 Predictive Utility of Patient-Reported Outcomes for Survival in 1st-Line Treated Patients with a NSCLC in EMPOWER-Lung 1 and 3

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S117

2023

Link zum Volltext

Verfügbarkeit prüfen

Variates of Survival in Metastatic Uveal Melanoma

Journal of clinical oncology, 2005-11, Vol.23 (31), p.8076-8080

2005

Link zum Volltext

Verfügbarkeit prüfen

1438P Cemiplimab for advanced non-small cell lung cancer: Squamous subgroup analysis for EMPOWER-Lung 1 and 3

Annals of oncology, 2023-10, Vol.34, p.S818-S818

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 625

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(526)
Mit Volltextzugriff
(573)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(302)
Life Sciences & Biomedicine
(285)
Humans
(269)
Female
(179)
Male
(178)
Psychiatry
(138)
Biological And Medical Sciences
(124)
Adult
(113)
Medical Sciences
(110)
Neurosciences
(85)
Neurosciences & Neurology
(85)
Psychology. Psychoanalysis. Psychiatry
(85)
Psychopathology. Psychiatry
(78)
Schizophrenia - Genetics
(76)
Genotype
(75)
Adult And Adolescent Clinical Studies
(74)
Bipolar Disorder - Genetics
(73)
Middle Aged
(72)
Schizophrenia
(72)
Genetics & Heredity
(68)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy

A phase I trial of the safety and pharmacokinetics of cemiplimab, a human monoclonal antibody to programmed death-1, in Japanese patients with advanced malignancies, including expansion cohorts for patients with non-small-cell lung cancer

Health Care Utilization And Cost Associated With Radioiodine Refractory (Rai-R) Differentiated Thyroid Cancer (DTC)

Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)

Treatment Patterns and Persistence Among Patients Treated with Stivarga

Compare Demographic and Clinical Characteristics Among Colorectal Cancer Patients with a Different Number of Treatment Lines in the United States Veterans Health Administration

Health Care Cost and Utilization Among Patients Treated with Stivarga

Descriptive Analysis Of Treatment Patterns And Mortality Of United States Veteran Patients With Colorectal Cancer

2862 The influence of time to objective response on lenvatinib clinical outcomes in the phase 3 SELECT trial

Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy

Prevalence of Hypogonadism among Men with Weight Loss Related to Human Immunodeficiency Virus Infection Who Were Receiving Highly Active Antiretroviral Therapy

Descriptive Analysis of Patients Initiating Regorafenib Therapy

1503TiP A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50

Evaluating Costs and Utilization of Prostate Cancer Patients with Bone Metastases in the Outpatient Hospital Setting

1443P Patient-reported outcomes (PROs) with cemiplimab plus chemotherapy (CEMI + CHEMO) for first-line treatment of advanced non-small cell lung cancer (aNSCLC): PD-L1 level subgroups in EMPOWER-Lung 3

P2.05-04 Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

P2.06-10 Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1

1105P Outcomes of real-world (RW) patients (pts) with advanced NSCLC (aNSCLC) and high programmed cell death-ligand 1 (PD-L1) expression receiving first line (1L) immune checkpoint inhibitor (ICI) therapy

1183P Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 1 histology subgroups

112P Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation

P1.15-12 Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1

334P Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Geographic region subgroups in EMPOWER-Lung 1

MA05.11 Predictive Utility of Patient-Reported Outcomes for Survival in 1st-Line Treated Patients with a NSCLC in EMPOWER-Lung 1 and 3

Variates of Survival in Metastatic Uveal Melanoma

1438P Cemiplimab for advanced non-small cell lung cancer: Squamous subgroup analysis for EMPOWER-Lung 1 and 3

Suchergebnisse filtern